Quest Diagnostics (DGX) EBIT (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of EBIT data on file, last reported at $399.0 million in Q1 2026.

• Quarterly EBIT rose 15.32% year-over-year to $399.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 15.59% YoY) and the FY2025 annual result came in at $1.6 billion, up 15.6% from the prior year.
• EBIT grew to $399.0 million in Q1 2026 per DGX's latest filing, from $386.0 million in the prior quarter.
• The five-year high for EBIT was $513.0 million in Q1 2022, with the low at $135.0 million in Q4 2022.
• Average EBIT over 5 years is $352.4 million, with a median of $355.0 million recorded in 2024.
• Year-over-year, EBIT slumped 74.81% in 2022 and surged 97.78% in 2023.
• Quest Diagnostics' EBIT stood at $135.0 million in 2022, then jumped by 97.78% to $267.0 million in 2023, then soared by 35.21% to $361.0 million in 2024, then advanced by 6.93% to $386.0 million in 2025, then rose by 3.37% to $399.0 million in 2026.
• Business Quant data shows DGX's EBIT at $399.0 million in Q1 2026, $386.0 million in Q4 2025, and $386.0 million in Q3 2025.